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Abstract 
 
Objective - Phosphoinositide 3-kinase α (PI3Kα) is a therapeutic target in oncology but its 
role in platelets and thrombosis remains ill characterized. In this study we have analyzed the 
role of PI3Kα in vitro, ex vivo and in vivo in two models of arterial thrombosis. 
Approach and results - Using mice selectively-deficient in p110α in the megakaryocyte 
lineage and isoform-selective inhibitors, we confirm that PI3Kα is not mandatory but 
participates to thrombus growth over a collagen matrix at arterial shear rate. Our data 
uncover a role for PI3Kα in low-level activation of the GPVI collagen receptor by contributing 
to ADP secretion and in turn full activation of PI3Kβ and Akt/PKB. This effect was no longer 
observed at high level of GPVI agonist concentration. Our study also reveals that over a von 
Willebrand factor matrix, PI3Kα regulates platelet stationary adhesion contacts under arterial 
flow through its involvement in the outside-in signaling of von Willebrand factor engaged 
αIIbβ3 integrin. In vivo, absence or inhibition of PI3Kα resulted in a modest but significant 
decrease in thrombus size following superficial injuries of mouse mesenteric arteries and an 
increased time to arterial occlusion following carotid lesion, without modification in the tail 
bleeding time. Considering the more discrete and non-redundant role of PI3Kα compared to 
PI3Kβ, selective PI3Kα inhibitors are unlikely to increase the bleeding risk at least in the 
absence of combination with antiplatelet drugs or thrombopenia. 
Conclusions – This study provides mechanistic insight into the role of PI3Kα in platelet 
activation and arterial thrombosis.  
 
 
249 words 
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Abbreviations 
 
ADP: adenosine diphosphate 
Akt/PKB: protein kinase B  
CRP: collagen-related peptide  
GP: glycoprotein  
KO: knockout  
PI3K: Phosphoinositide 3-kinase   
VWF: von Willebrand factor 
WT: wild type 
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Introduction 
 
Platelet adhesion and aggregation at sites of vascular injury are essential for normal 
hemostasis. However, in diseased vessels, platelet accumulation after erosion or rupture of 
an atherosclerotic plaque can cause occlusive thrombosis leading to ischemic diseases, a 
major cause of death and disability worldwide. Von Willebrand factor (VWF) plays a key role 
in hemostasis by promoting adhesion and spreading of platelets on exposed subendothelial 
matrix proteins following arterial injury. Under conditions of rapid blood flow, the glycoprotein 
(GP) Ib/IX/V mediates the initial platelet recruitment through its binding to VWF exposed in 
the subendothelium.1 Interaction of GPIb/IX/V with VWF not only mediates platelet rolling and 
transient adhesion but also initiates a signaling cascade leading to platelet integrin αIIbβ3 
activation (inside-out signaling). Under its high affinity state, αIIbβ3 can interact with fibrinogen 
but also with the RGD sequence of the carboxyl-terminal region of VWF, contributing to 
stable adhesion contact of platelets to VWF under flow conditions. Platelets also interact with 
collagen through GPVI and α2β1 leading to strong platelet activation, spreading and secretion 
and in turn thrombus formation. The molecular mechanisms linking GPIb/VWF interaction to 
platelet activation remain incompletely characterized although several signaling proteins 
have been implicated, including phosphoinositide 3-kinases (PI3Ks).1 
Over the last decade, class I PI3Ks have been the subject of intense research in several 
cells types including platelets.2,3 Class I PI3Ks (PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ) are 
important signaling enzymes producing the lipid second messenger 
phosphatidylinositol(3,4,5)trisphosphate (PI(3,4,5)P3) which, through binding to proteins, 
organizes functional signal transduction modules.4 All Class I PI3Ks are expressed in 
platelets. PI3Kδ has modest role in platelets, PI3Kγ is mainly implicated downstream of the 
ADP receptor P2Y12 and PI3Kβ has a major role in platelet signaling. Using pharmacological 
inhibitors and genetic approaches, we and others have demonstrated that PI3Kβ acts 
downstream of most platelet receptors and integrins 5-9  and is critical to maintain the integrity 
of the thrombus at high shear rate in contrast to PI3Kα.3, 10 The absence of PI3Kβ cannot be 
compensated by PI3Kα, suggesting complementary actions for these two PI3Ks during 
platelet activation.  
PI3Kα has been involved in IGF-1-mediated potentiation of platelet function.11, 12 Moreover, 
using pharmacological inhibitors it has been suggested that PI3Kα and β are both required 
for full platelet activation by collagen 8, 9, 13. While Gilio et al. 8 could not distinguish 
differences in the degree of involvement of PI3Kα and β isoforms in platelets activation by 
GPVI agonist, Kim and al. 9 showed a smaller implication of PI3Kα in GPVI-mediated platelet 
responses. To precise the role of platelet PI3Kα in hemostasis and thrombosis, we 
performed a comprehensive study using both, a mouse model in which p110α is selectively 
inactivated in megakaryocyte lineage 10 and two selective inhibitors, A66 and INK1117 (or 
MLN1117) 14, 15, the latter being in a phase I clinical trial for oncology indications.16 
Our data uncover a role for PI3Kα in low-level of GPVI activation by contributing to ADP 
secretion and in turn full PI3Kβ and Akt/PKB activation. This specific effect was no longer 
observed at high level of GPVI agonist concentration. Our study also reveals that PI3Kα is 
implicated in the control of platelet stationary adhesion contact over VWF under shear by 
acting downstream of VWF-engaged αIIbβ3 in both, mouse and human. As a consequence, 
absence or inhibition of PI3Kα in platelets decreased arterial thrombus formation in two 
models of arterial thrombosis in mouse, without modification of the tail bleeding time.  
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Materials and Methods 
 
Reagents and Antibodies: Collagen Reagent HORM® (equine) suspension was purchased 
from Takeda. DIOC6 was purchased from Life Technologies. Antibody against p-Akt was 
purchased from Cell Signaling and Akt from Sigma Aldrich. Antibody against VWF was 
purchased from DAKO. The selective PI3Kα inhibitor INK1117 was from Takeda 
Pharmaceuticals USA, Inc and A66 was from Selleckchem. Ristocetin was from Stago and 
Integrilin® was provided by Glaxo PEG-400 (Polyethylen glycol–400 grade) was from Fisher 
Scientific UK. Group Ltd. Serotonin ELISA test was from IBL International. CRP was from Pr. 
Richard Farndale laboratory (Cambridge, UK). Botrocetin was from Dr. Pierre Mangin 
laboratory (Strasbourg, France). Wilfactin was purchased from LFB biomedicaments 
(France). Murine VWF was from Cécile Denis (Paris, France). All other reagents were 
purchased from Sigma-Aldrich. 
 
Mice: All animal procedures were in accordance with the guidelines of the Ethics Committee 
on Animal Experimentation and with the French Ministry of Agriculture license 
(http://anexplo.genotoul.fr). PF4-cre/p110αflox/flox mice (83 males and females) and their 
p110αflox/flox wild-type (77 males and females) littermates were generated as previously 
described10 and are further referred to as p110αnull or WT. These animals (C57Bl/6J genetic 
background; 10 backcrosses) showed normal platelet size and count. Males and females 
were indifferently used since preliminary analysis revealed no differences between control 
males and females in the parameters measured in this study. 
 
Preparation of washed mouse platelets and in vitro aggregation studies are described 
in the supplemental Methods.  
 
Preparation of washed human platelets: Blood from healthy donors was purchased from 
the Etablissement Français du Sang (Toulouse) and immediately processed for experiments. 
Blood was collected into ACD anticoagulant and platelets were isolated by successive 
centrifugation steps essentially as described previously.17  
 
Flow assays on collagen, VWF or fibrinogen are described in the supplemental Methods. 
Briefly, mouse or human blood was drawn into heparin sodium (10 IU/ml). When indicated, 
human blood was incubated at 37°C with INK1117 (1 µmol/L) or A66 (1 µmol/L) during 10 
min. Labeled blood was then perfused through a microcapillary for the indicated time at a 
wall shear rate of 250 sec-1, 1,500 sec-1 or 4,000 sec-1 according to the matrix. Platelet 
adhesion and thrombus formation was visualized with a 40x oil immersion objective.  
 
Serotonin secretion: Serotonin content was measured using IBL Serotonin ELISA test 
(RE59121, IBL) according to manufacturer instructions.  
 
Static adhesion assay is described in the supplemental Methods. Briefly, glass coverslips 
were coated with murine VWF 18. Washed mouse platelet suspension (106 platelets) were 
preincubated or not with Integrilin and botrocetin (2 µg/ml) for 10 min at 37°C, and allowed to 
adhere to VWF surface. For experiment with ristocetin, human platelet were preincubated 
with ristocetin and, when indicated, with the selective PI3Kα inhibitors INK1117 (0.5 µmol/L) 
or A66 (1 µmol/L) for 10 min at 37°C, and allowed to adhere to VWF surface (Wilfactin).  
 
Laser-induced vessel wall injury is described in the supplemental Methods. 19 
 
Mouse treatment with INK1117: INK1117 was resuspended in a solution of 5% NMP (1-
Methyl-2-pyrrolidinone) and 95% PEG-400 (Polyethylen glycol–400 grade) at the 
concentration of 12 mg/ml. Mice (8 weeks old C57Bl/6J males and females) were treated by 
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INK1117 at 60 mg/kg bodyweight or vehicle by gavage. Experiments were performed 5 hours 
after drug intake.  
 
Tail bleeding time is described in the supplemental Methods. 
FeCl3 induced carotid artery Thrombosis is described in the supplemental Methods 
 
Statistical Analysis: Data are expressed as mean ± standard error of the mean (SEM). 
Data were analyzed first by Shapiro-Wilk test and D’Agostino-Pearson test to confirm the 
normal distribution. Significance of differences was determined using 2-tailed Student t test, 
1-way ANOVA or 2-way ANOVA, and a Bonferroni post-hoc analysis. P values, P<0.05 was 
considered statistically significant (*p<0.05, **p<0.01, ***p<0.001). All statistical analyses 
were performed using GraphPad Prism 6 software. 
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Results 
 
PI3Kα contributes to thrombus growth over collagen under shear conditions  
To establish the role of platelet p110α in platelet function in vitro and in vivo, we used our 
PF4-Cre/p110αflox/flox mouse model in which p110α is selectively deficient in the 
megakaryocyte lineage (hereafter called p110αnull). The specific deletion of p110α in platelets 
had no effect on the expression of the other platelet class I PI3K isoforms or surface 
glycoproteins GPIb, GPIIb (αIIb) and GPVI.10  
We first investigated platelet adhesion and thrombus formation on fibrilar type I collagen 
matrix using a microfluidic system under normal and pathological arterial blood flow. The 
surface covered by platelets and the thrombus volume were monitored by video microscopy 
during perfusion of heparinized whole blood from wild type (WT) or p110αnull platelet mice. 
After 2 min of flow at an arterial shear rate of 1,500 sec-1, WT platelets formed stable thrombi 
while the surface covered by p110αnull platelets and the thrombus volume were significantly 
reduced (Figure 1A). At longer time of perfusion these differences were reduced and even 
undetectable after 4 min of flow when the thrombi size reached a plateau (Figure 1A). In an 
another set of experiments, the thrombi formed at a shear rate of 1,500 sec−1 during 90 sec 
were then submitted to a pathological shear rate of 4,000 sec-1 (Figure 1B). A significant 
difference was still observed after 30 sec of flow but then tended to be reduced and was no 
longer significant (Figure 1B). Of note, under this high shear condition, the stability of the 
thrombi was comparable in WT and p110αnull platelet mice. The specific role of PI3Kα lipid 
kinase activity in thrombus growth was confirmed in similar experiments using heparinised 
human whole blood treated with the selective PI3Kα inhibitors A66 (1µM) or INK1117 
(1µM)14,15 (Figure 1C). The two PI3Kα selective inhibitors reproduced the effect observed 
using blood from p110αnull nice. 
These results indicate that PI3Kα was not mandatory but significantly contributed to 
thrombus growth at physiological or pathological shear rate over a collagen matrix and this 
effect was due to the catalytic activity of PI3Kα.  
 
 
PI3Kα is involved in aggregation and Akt activation following engagement of GPVI 
by low agonist concentrations  
Washed platelets were then stimulated with different agonists triggering either G-protein-
coupled receptors (GPCR) (including TxA2 analogue (U46119), thrombin and ADP) or the 
collagen receptor GPVI, which uses the ITAM motif of the Fc receptor γ-chain (FcRγ) to 
stimulate platelets via tyrosine kinases, following addition of collagen-related peptide (CRP) 
or collagen. A decreased aggregation response to low concentrations of CRP or collagen 
was observed in p110αnull platelets (Figure 2). However, increasing the concentrations of 
GPVI agonists restored a normal aggregation. Platelet aggregation response was normal in 
response to U46119, thrombin or ADP, whatever the concentration used (Figure 2).  
One of the critical downstream effectors of class I PI3K is the Ser/Thr kinase Akt/PKB. 20 As 
shown in Figure 3Ai, the lack of PI3Kα did not affect Akt phosphorylation following U46619 or 
thrombin stimulation, even at low doses of agonists. Conversely, p110αnull platelets 
stimulated by a low dose of CRP (1 µg/ml) showed a strong decrease in Akt phosphorylation. 
Consistent with the aggregation results, this difference was no longer observed at higher 
concentrations of CRP (Figure 3Ai). The phosphorylation of both Ser473 and Thr308 of Akt 
was reduced at low doses of CRP (1 µg/ml) and this difference was observed at any time of 
stimulation tested (Figure 3Aii). Importantly, invalidation or inhibition of class I PI3Kβ fully 
inhibited Akt phosphorylation (Figure 3Aiii), indicating that while PI3Kα is important for Akt 
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activation at low level of GPVI activation, PI3Kβ is mandatory. Since platelet activation and 
Akt phosphorylation by collagen or CRP are dependent on ADP and P2Y12 21, 22 we 
investigated the potential implication of PI3Kα on platelet secretion. Serotonin release was 
measured as a read-out of dense granule secretion. Absence or inhibition of PI3Kα reduced 
platelet dense granule secretion induced by a low dose of CRP (Figure 3B). Interestingly, 
addition of low doses of ADP, unable to induce Akt phosphorylation, could rescue Akt 
phosphorylation induced by 1 µg/ml CRP in the absence of PI3Kα (Figure 3C). As illustrated 
in Figure 3D, these results revealed a critical role of PI3Kα in initiating the stimulation of 
platelets exposed to low concentrations of GPVI agonist by contributing to ADP secretion 
and in turn full activation of PI3Kβ and Akt. 
 
PI3Kα plays an important role in the stationary adhesion contact of platelets over VWF 
under flow 
We then analyzed by microfluidic and videomicroscopy the role of PI3Kα in the interaction of 
platelets on immobilized murine VWF during perfusion of heparinized whole blood at high 
shear rate (4,000 sec-1) to challenge GPIb/VWF interactions. Platelet translocation and rolling 
was recorded continuously (Video 1 and Figure 4). As expected, WT platelets presented 
reversible contacts leading to platelet translocation and rolling over VWF.23 Interestingly, 
p110αnull platelets translocated and rolled over the VWF matrix but exhibited much shorter 
stationary adhesion contact compared to WT as shown by the typical tracking profiles (Figure 
4A). After 2 min of flow, quantification indicated that WT platelets spend 76% of their time in 
arrest versus 36% for p110αnull platelets (Figure 4B). Consistent with this, real-time analysis 
revealed that p110αnull platelets had a significantly higher velocity compared to WT platelets 
(12.4 µm/s ± 1.5 for p110αnull vs 6.2 µm/s ± 1.6 for WT platelets, p≤0.01, n=6) (Figure 4C). 
This result correlated with a higher distance covered by p110αnull platelets between each 
arrest, compared to WT platelets (14.5 µm ± 3.2 for p110αnull and 5.1 µm ± 1.1 for WT 
platelets, p≤0.01, n=6) (Figure 4D). Moreover, when heparinized human blood, treated with 
INK1117 (1µM) for 10 min, was perfused over immobilized human VWF at 4,000 s-1 for 3 
min, we observed a significant decrease in platelet stationary adhesion contacts 
(Supplemental Figure I). 
These data indicated that PI3Kα was either involved in the molecular mechanisms linking 
VWF-GPIb/IX/V complex interaction to integrin αIIbβ3 inside-out activation or in the outside-in 
signaling from this integrin engaged by VWF C4 domain to allow stable platelet adhesion. 
To investigate whether PI3Kα is involved in the general αIIbβ3 outside-in signaling, 
heparinized whole blood from WT or p110αnull platelet mice was perfused over a fibrinogen-
coated surface at a low shear rate of 250 sec-1 for 160 sec and then at 1,500 sec-1 for 120 
sec (Supplemental Figure IIA). Integrin αIIbβ3 outside-in signaling is known to stabilize and 
sustain αIIbβ3 adhesive bonds necessary for the maintenance of firm adhesion contacts under 
shear.24 Absence of PI3Kα did not affect stable platelet adhesion to immobilized fibrinogen 
whatever the shear applied (250 or 1,500 sec-1). Moreover, the spreading of WT or p110αnull 
platelets on a fibrinogen-coated surface in the presence of 0.3 unit/ml thrombin in static 
conditions was comparable between p110αnull (15.36 ± 1.52 µm2) and WT (16.45 ± 1.53 µm2) 
platelets (Supplemental Figure IIB). These results indicated that PI3Kα was not required for 
αIIbβ3 outside-in signaling following engagement of the integrin by immobilized fibrinogen 
either under flow or static conditions. 
 
PI3Kα mediates platelet spreading on VWF in a αIIbβ3-dependent manner  
We next investigated the ability of p110αnull platelets to extend filopodia on immobilized 
murine VWF matrix under static conditions in the presence of botrocetin (2 µg/ml), a 
component of the Bothrops jararaca venom known to bind to the VWF A1 domain allowing 
platelet activation through a GPIb-specific mechanism, independently of αIIbβ3.25,26 To assess 
a potential role of PI3Kα specifically downstream of GPIb-IX-V, the interaction of αIIbβ3 with 
VWF was blocked by Integrilin. As shown in the scanning electron micrographs (Figure 5A, 
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left panel), in the presence of Integrilin, VWF was able to support filopodia formation in WT 
platelets through a GPIb-dependent and αIIbβ3-independent mechanism. Filopodia formation 
of p110αnull platelets (right panel) was indistinguishable from WT platelets (Figure 5A) as 
confirmed by observation of the actin cytoskeleton by confocal microscopy (Figure 5B). This 
result indicated a normal GPIb signaling towards filopodia formation in the absence of PI3Kα. 
Another set of experiments was then designed to investigate the role of PI3Kα in lamellipodia 
formation on immobilized VWF in the presence of ristocetin, a bacterial glycopeptide that 
binds to the proline-rich region of the A1 domain in VWF. Of note, ristocetin is not 
recommended for mouse platelets studies.27, therefore we used human platelets. 
VWF/ristocetin is known to generate full spreading and robust stress fiber formation through 
a pathway that is dependent on αIIbβ3.25,26 In absence of ristocetin, human platelets were 
unable to spread on VWF (Supplemental Figure III). Forty minutes after addition of untreated 
washed human platelets on VWF in the presence of ristocetin, we observed an enrichment of 
cortical F-actin at the cell periphery and stress fibers in the center of spread platelets (Figure 
5C, left panel). Interestingly, two unrelated selective inhibitors of p110α (INK1117 and A66) 
strongly affected actin reorganization and significantly reduced the mean platelet spreading 
(Figure 5C).  
We then investigated WT and p110αnull platelets spreading on VWF matrix in the presence of 
the secondary agonist ADP. After 60 min, WT murine platelets spread to some extent, 
formed lamellae-like structure and some filopodia. This was strongly affected by the absence 
of PI3Kα as shown by quantification of the platelet area (Figure 5D). In both genotypes, 
spreading was prevented by addition of Integrilin, highlighting the importance of integrin αIIbβ3 
outside-in signaling in this process.  
Taken together, these results show that PI3Kα is an important component of αIIbβ3 outside-in 
signaling on immobilized VWF but not on immobilized fibrinogen.  
 
Lack of platelet PI3Kα affects thrombus formation in vivo without increasing the 
bleeding time 
We next evaluated the consequence of the lack of platelet PI3Kα in primary hemostasis and 
thrombus formation in vivo. The tail bleeding time of the p110αnull platelet mice was not 
significantly different from control mice and the treatment of WT mice with the PI3Kα inhibitor 
INK1117 (60 mg/kg bodyweight) had no impact (Figure 6A). Moreover, we never observed 
re-bleeding in PI3Kαnull platelet mice. These data suggested that primary hemostasis was 
spared in the absence of platelet PI3Kα activity. We next monitored platelet thrombus 
formation by intravital microscopy following laser beam-induced local injury of mesenteric 
arterioles (Figure 6B). Two types of lesions can be performed by this approach. A deep injury 
leading to the formation of a thrombus dependent on VWF and thrombin and a superficial 
lesion that generates a thrombus largely dependent on collagen and VWF.19 Following deep 
injury, thrombus formation tended to be slightly reduced in p110αnull platelet mice compared 
to WT mice but the difference was not significance (Figure 6B, lower panel). In contrast, 
superficial injury of the mesenteric artery induced the formation of a significantly smaller 
thrombus in p110αnull platelet mice as compared to WT mice (364 ± 66 µm2 in WT versus 166 
± 43 µm2 in p110αnull platelet mice at 30 sec, *p = 0.0181) (Figure 6B, upper panel).  
Another model of experimental arterial thrombosis triggered by carotid injury with ferric 
chloride (FeCl3) was tested. While WT mice had a mean occlusion time of 7.3 ± 0.3 min after 
injury, among eleven p110αnull platelet mice, nine needed a significantly longer time to 
occlude (mean occlusion time: 12.8 ± 1.1 min) and the two other mice did not occlude during 
the 30 min of analysis (Figure 6C, left panel). Similar results were obtained with mice fed with 
the PI3Kα inhibitor INK1117 (60 mg/kg) and subjected to FeCl3 lesion 5 hours later (Figure 
6C, right panel). These results were consistent with the ex vivo data and demonstrated a 
contribution of PI3Kα catalytic activity to the mechanisms of thrombus formation following 
arterial injury in vivo. 
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Discussion 
 
A non-redundant contribution of PI3Kα and β in GPVI signaling was suggested by studies 
using a pharmacological inhibitor in vitro 8, 9. In the current study we confirm that, besides a 
major role of PI3Kβ, 5 PI3Kα also contributes to GPVI signaling and propose a mechanistic 
explanation. Indeed, following activation by low doses of GPVI agonists, PI3Kα participate to 
secretion and that secreted ADP then allows a full activation of PI3Kβ which has the major 
role in producing PtdIns(3,4,5)P3 downstream of GPVI 28. Accordingly, addition of low doses 
of ADP could rescue Akt phosphorylation in PI3Kα-deficient platelets stimulated by low 
concentration of CRP. Our results also show that PI3Kα was dispensable as soon as the 
concentrations of GPVI agonists (CRP or collagen) increased. It is noteworthy that while 
PI3Kβ was mandatory for platelet activation whatever the doses of GPVI agonists used, it 
was unable to compensate the loss of PI3Kα when GPVI is mildly activated. Consistent with 
these results we recently observed that the mass of PI(3,4,5)P3 produced was weakly (20%) 
but significantly decreased in p110αnull platelets stimulated by CRP 28. The identification of 
this new regulatory loop (Figure 3D) shed light on the complementary and non-redundant 
role of class I PI3Kα and PI3Kβ in platelets. PI3Kα being activated by binding to tyrosine 
phosphorylated residues and, in contrast to PI3Kβ, being independent of the β/γ subunits of 
heterotrimeric Gi-proteins, it can be stimulated independently of ADP secretion and P2Y12 
activation 22. Thus, our data together with those from Hers et al. and Kim et al. 11, 12 indicate 
that PI3Kα is an important lipid kinase in platelet priming or activation by low doses of 
agonists acting through receptors coupled to tyrosine kinase activation. 
 
Using both p110αnull platelet mice and selective inhibitors-treated human or mouse blood we 
found that PI3Kα was not mandatory but was significantly implicated in ex vivo thrombus 
formation on collagen at a physiological arterial shear rate. Indeed, while p110αnull platelets 
formed smaller thrombi during the early phase of blood perfusion this difference was no 
longer detectable after a prolonged period of flow when the thrombi size reached a plateau. 
These data are consistent with those from Gilio et al. 8 using PIK-75 inhibitor-treated human 
or mice blood however the phenotype observed in their study was much stronger than in our 
study possibly because of PIK-75 off-target effects. In contrast, Blair et al.29 did not observe 
thrombus formation defect on collagen in the absence of PI3Kα. This discrepancy could be 
explained by differences in the experimental conditions, particularly by the presence of 
calcium chelator, since the authors used whole blood anticoagulated with citrate, heparin, 
and PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone) whereas we only used 
heparin. 
Of note, as we previously observed in p110αnull platelets 10, PI3Kα inhibitors (INK1117 and 
A66) did not affect thrombus stability. These data suggest that amplification of signaling 
loops within the core of the thrombus via low diffusion of released agonists and sustained 
αIIbβ3 activation 30 is not dependent on PI3Kα. In contrast, PI3Kβ is critical to control 
thrombus stability at high shear rate 10 because it is an essential component of the outside-in 
signaling of various integrins, including αIIbβ3 engaged by fibrinogen and of ITAM signaling.31  
 
Another important new observation is the involvement of PI3Kα in platelet stationary 
adhesion contact over VWF surface under shear. The interaction of VWF with GPIb allows 
surface translocation (rolling) that continues until platelets become activated. At that point, a 
second step mediated by αIIbβ3, not required for the initial attachment, supports stationary 
adhesion contacts of individual platelets via interaction of αIIbβ3 with the C4 domain of VWF, 
leading to an outside-in signaling and a subsequent cytoskeleton reorganization.1, 20 The 
engagement of αIIbβ3 strengthens the interaction of platelets with the adhesive surface 
resulting in a marked decrease in velocity and in turn to stationary contact.23, 32,33 Several 
signaling molecules have been implicated downstream of GPIb/IX/V, including PI3K. 1 
However, the implication of PI3K in GPIb-dependent αIIbβ3 inside-out 34 or outside-in 
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signaling, 25, 35 or both, is still a matter of debate and the PI3K isoform(s) involved are 
unknown. Here, we show that PI3Kα was not required for the GPIb-dependent platelet 
translocation and rolling over VWF but was important downstream of integrin αIIbβ3 to allow 
stationary adhesion contact. Furthermore, no defect in platelet adhesion on immobilized 
fibrinogen under flow or spreading in static conditions was observed, indicating a 
requirement of PI3Kα downstream of αIIbβ3 engaged by binding to immobilized VWF but not 
in the outside-in signaling of fibrinogen-engaged αIIbβ3, in contrast to PI3Kβ.5 This suggests 
that distinct domains or different affinities for VWF and fibrinogen could be implicated in αIIbβ3 
binding that may elicit different pathways of activation as previously proposed.36, 37 
 
Mice in which p110α is selectively deficient in the megakaryocyte lineage had normal platelet 
count 10 and tail bleeding time, consistent with the fact that platelet rolling on VWF was 
spared and that they responded normally to TXA2, ADP, thrombin and high concentration of 
GPVI agonists. Interestingly, these mice exhibited a significant decrease in arterial thrombus 
formation in two different models of experimental thrombosis. In laser-induced thrombosis in 
mesenteric arterioles with superficial injury, the thrombus, known to be dependent on GPVI-
collagen and GPIb-VWF interactions, was significantly smaller in the absence of platelet 
PI3Kα. In response to a deep mesenteric artery lesion, where the thrombus formed is 
thrombin-dependent 19 absence of platelet PI3Kα had no significant effect. By comparison 
with anti-platelet drugs like clopidogrel or αIIbβ3 blockers tested in the same model 38 our data 
suggest a weaker impact of PI3Kα inhibition on thrombus formation. 
In the model of arterial thrombosis triggered by carotid injury with FeCl3,39 the time from injury 
to complete occlusion of the artery was significantly prolonged in p110αnull platelet mice. This 
model of thrombosis is known to require thrombin and VWF. These data are consistent with 
the fact that the interaction of platelets to VWF through integrin αIIbβ3 contributes to thrombus 
growth.40, 41  
We also used PI3Kα inhibitors in vivo to directly analyze the implication of the lipid kinase 
activity. As observed in p110αnull platelet mice, pharmacological inhibition of p110α with 
INK1117 had no significant impact on the tail bleeding time and reproduced the defect of 
thrombus formation following FeCl3 carotid injury. This is important information since 
selective inhibitors of PI3Kα, including INK1117, are now in clinical trials in the treatment of 
cancer with gain of function mutations in p110α gene.16, 42 Our data suggest that PI3Kα 
inhibitors, on their own, are unlikely to increase the bleeding risk as also observed in mouse 
treated during 7 days with PIK-75  or with a specific siRNA.43 Accordingly, a clinical trial with 
INK1117 did not show particular bleeding.16 However, associations of these inhibitors with 
antiplatelet drugs and their use in patients with thrombopenia have not been tested. 
 
In conclusion, using both a genetic approach and pharmacological inhibitors this study, 
provides new mechanistic insight into the role of PI3Kα in platelets activation and arterial 
thrombosis.  
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Highlights 
 
 PI3Kα contributes to platelet aggregation at low level of GPVI activation by 
participating to ADP secretion and in turn PI3Kβ and Akt activation. 
 PI3Kα regulates stationary adhesion on VWF under shear by acting downstream of 
VWF-engaged αIIbβ3. 
 PI3Kα contributes to arterial thrombus growth in vivo. 
 On their own, PI3Kα inhibitors developed for cancer therapy should not increase the 
bleeding risk. 
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Figure legends 
 
Figure 1: PI3Kα is implicated in thrombus formation ex vivo under shear rate. (A) 
DIOC6-labeled platelets in whole blood from WT or p110αnull mice were perfused through a 
collagen-coated microcapillary at a shear rate of 1,500 sec−1 during 240 sec. Representative 
images of thrombus formation over time are shown. Surface covered by platelet thrombi (%) 
and thrombi volumes (µm3) were analyzed using ImageJ software (mean ± SEM; n = 6 
independent experiments; **p <0.01 and *p<0.05 vs WT according to 2-way ANOVA test). 
(B) Whole blood from WT or p110αnull mice was perfused through a collagen-coated 
microcapillary at a shear rate of 1,500 sec−1 during 90 sec and then at a high shear rate of 
4,000 sec−1. Thrombi volumes (µm3) were analyzed using ImageJ software (mean ± SEM; n 
= 4 to 5 independent experiments; ***p <0 .001 and **p <0.01 vs WT according to 2-way 
ANOVA test). (C) Human blood pre-incubated during 10 min with DMSO, INK1117 (1µM) or 
A66 (1µM) was perfused through a collagen-coated microcapillary at a shear rate of 1,500 
sec−1 during 90 sec and then at a high shear rate of 4,000 sec−1. Thrombi volumes (µm3) 
were analyzed using ImageJ software (mean ± SEM; n = 3 independent experiments; ***p <0 
.001, **p <0.01 and *p<0.05 vs DMSO according to 2-way ANOVA test). Representative 
images of thrombus formation over time and 3D surface plot of the time point 90 sec are 
shown. 
 
Figure 2: PI3Kα is implicated in platelet aggregation at low concentrations of CRP. 
Washed platelets from WT or p110αnull mice were stimulated with collagen, CRP, U46619 or 
thrombin and aggregation was assessed using a Chrono-log dual-channel aggregometer 
under stirring for 5 min. For ADP, whole blood from WT or p110αnull mice was drawn into 
heparin (5 000 IU/ml) and was stimulated with ADP and aggregation was assessed during 5 
min. The profiles shown are representative of 5 independent experiments. Quantifications of 
the maximum of aggregation at 5 min are shown on right panels (mean ± SEM; n = 5 
independent experiments; ***p <0 .001 and *p<0.05 vs WT according to 2-tailed Student t 
test). 
  
 
Figure 3: PI3Kα is implicated in Akt phosphorylations at low concentrations of CRP. 
(A) (i) Platelets from WT or p110αnull mice were stimulated by U46619, thrombin or CRP 
during 5 min at the indicated concentration. Lysates were submitted to immunoblotting with 
anti-Akt-Ser(P)473 or Akt antibodies (control loading), as indicated. (ii) Platelets were 
stimulated by CRP (1µg/ml) during indicated time. Quantifications by densitometric analysis 
of the western blots (Akt-Ser(P)473 and -Thr(P)308) are shown (mean ± SEM; n = 4 
independent experiments; **p <0.01 and *p<0.05 vs WT at independent time point according 
to 2-tailed Student t test). (iii) WT or p110βnull platelets were preincubated or not with the 
PI3Kβ inhibitor AZD6482 (1µM) during 10 min and stimulated by CRP (1 µg/ml) during 5 min. 
Quantifications by densitometric analysis of the Western blots of Akt-Ser(P)473 are mean ± 
SEM of 3 independent experiments (***p <0 .001 vs WT according to 1-way ANOVA test). 
(B) Role of p110α in promoting dense granule secretion. WT or p110αnull platelets were 
stimulated by CRP (1 or 3 µg/ml) in presence of fluoxetine (25 µM) to prevent serotonin re-
uptake, with or without the PI3Kα inhibitor A66 (1µM). Secreted serotonin was quantified by 
ELISA assay. Data are expressed as concentration of serotonin secreted from 1.5 107 
platelets (mean ± SEM; n = 3 independent experiments; *p<0.05 vs WT according to 1-way 
ANOVA and 2-tailed Student t test). (C) ADP addition rescues Akt phosphorylation in 
p110αnull platelets stimulated by 1 µg/ml CRP. Platelets from WT or p110αnull mice were 
stimulated or not by CRP (1µg/ml) in the absence or presence of ADP at different 
concentrations as indicated. Lysates were submitted to immunoblotting with anti-Akt-
Ser(P)473 or Akt antibodies (control loading). Quantifications by densitometric analysis of the 
western blots are shown (mean ± SEM; n = 3 independent experiments; ***p<0.001 and 
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**p<0.01 according to 2-way ANOVA test). (D) Schematic representation of the role of PI3Kα 
in platelets stimulated by low doses of GPVI agonist. Following a weak GPVI activation, 
PI3Kα contributes to ADP secretion (1) which, via the β/γ subunits of its P2Y12 receptor, 
allows a full activation of PI3Kβ (2) which has a major role downstream of GPVI. The fact that 
PI3Kα cannot be replaced by PI3Kβ suggests that, under this condition, these kinases have 
complementary and non redundant roles.  
 
Figure 4: PI3Kα is essential for stationary adhesion contact of platelets over VWF 
matrix under flow. (A) Unlabeled platelets in whole blood from WT or p110αnull were 
perfused through a murine VWF-coated microcapillary at a shear rate of 4,000 sec−1 during 3 
min (Video 1 and representative images of both genotypes). Representative tracking profiles 
of platelet arrest or in motion are shown for both genotypes over a period of 30 sec of flow. 
(B) Graph showing the mean time (in %) of platelets stopped or in movement during the flow 
over VWF for both genotypes. (C) The velocity of platelets was evaluated in µm/sec (mean ± 
SEM; n = 6 independent experiments for each genotype with 30 platelets counted per 
experiment ***p<0.001 vs WT according to 2-tailed Student t test). (D) Graph showing the 
mean distance (µm) covered by platelets between each arrest for both genotypes (mean ± 
SEM; n = 6 independent experiments for each genotype with 30 platelets counted per 
experiment; **p<0.01 vs WT according to 2-tailed Student t test). 
 
Figure 5: PI3Kα is not implicated in GPIb/IX/V-mediated filopodia formation on VWF. 
Washed platelet suspensions from WT or p110αnull mice were incubated with botrocetin in 
presence of integrilin and adhered to VWF surface for 30 min. (A) Platelets were then 
examined by scanning electron microscopy and representative images are shown, scale bar 
10µm, 3 independent experiments. Filopodia per platelet, of both conditions was quantified 
manually and shown in right panel graphs. (mean ± SEM; n = 3 independent experiments for 
each genotype with an average of 50 platelets counted per experiment; 2-tailed Student t 
test). (B) Platelets were stained with FITC-conjugated phalloidin antibody for confocal 
microscopy imaging and representative images are shown, scale bar 5 µm, 4 independent 
experiments. PI3Kα mediates αIIbβ3-dependent platelet spreading on VWF. (C) Washed 
platelets suspension from human were incubated with ristocetin, in presence or not of the 
PI3Kα selective inhibitor INK1117 (0.5 µM) or A66 (1 µM), and adhered to VWF surface for 
40 min. Platelets were then stained with FITC-conjugated phalloidin antibody for confocal 
microscopy imaging. Representative images are shown, scale bar 10 µm, 3 independent 
experiments. Platelets area was analyzed using ImageJ software (mean ± SEM; n = 3 
independent experiments with an average of 400 to 500 platelets counted per experiment; 
***p<0.001 vs control according to 1-way ANOVA test). (D) Washed platelets from WT or 
p110αnull mice were allowed to adhere to a VWF surface for 60 min in the presence of ADP 
(10 µM) and in the absence or presence of the αIIbβ3 inhibitor integrilin, and stained with 
FITC-conjugated phalloidin antibody for confocal microscopy imaging. Representative 
images are shown, scale bar 5 µm, 3 independent experiments. Platelets area was analyzed 
using ImageJ software. (mean ± SEM; n = 3 independent experiments with an average of 
400 to 500 platelets counted per experiment; ***p<0.001 according to 2-way ANOVA test).  
 
Figure 6: Mice lacking PI3Kα have normal bleeding time, form smaller thrombi in vivo 
following superficial injury and present a decreased occlusion velocity after FeCl3-
induced carotid injury. (A) Absence (left panel) or pharmacological inhibition (right panel) of 
PI3Kα in platelets has no effect on bleeding time. Tail bleeding time was performed on WT (n 
= 6), p110αnull (n = 6) or WT mice treated with vehicle (Ve) (n = 12) or PI3Kα inhibitor 
(INK1117) (n = 14). (B) PI3Kα is required for thrombus growth in vivo after superficial laser-
induced injury of mesenteric arterioles. Superficial (upper panel) or deep (lower panel) laser 
injuries of mesenteric arterioles were performed in WT (n = 10) or p110αnull (n = 10) mice. 
Thrombus formation was monitored over time by fluorescence microscopy and typical 
profiles are shown for each condition. The mean thrombus area was analyzed at 0.3 second 
intervals, and the shading over the curve represents the SEM at each time point. Bar graphs 
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represent the area of the thrombus at t = 30 sec or t = 200 sec after injury and are expressed 
as the mean ± SEM (*p<0.05). Upper panel: n = 19 vessels in 6 WT mice, n = 18 vessels in 7 
p110α-deficient platelet mice. Lower panel: n=4 vessels in 4 WT mice, n=6 vessels in 5 
p110α-deficient platelet mice. (C) Thrombotic response of mice to ferric chloride injury of the 
carotid artery. Left panel: Flow rates were measured in the carotid artery from WT or 
p110αnull mice after exposure to 7% FeCl3 for 3 min. The experiment was stopped after 30 
min. For both genotype (n = 9), the time necessary to form a stable occlusion is shown for 
each mouse. Right panel: WT mice were treated with the PI3Kα inhibitor INK1117 (60 mg/kg, 
n = 12) or vehicle (Ve, n = 8) and subjected to FeCl3 lesion 5 hours later. The experiment 
was stopped after 30 min. For both conditions, the time necessary to form a stable occlusion 
is shown for each mouse (***p<0.001 and *p<0.05 vs WT or Ve according to 2-tailed Student 
t test). 
 
 
 






